As we mark World Antimicrobial Resistance (AMR) Awareness Week Nov. 18-24, the message is a familiar one: drug-resistant infections are rising, our antibiotics are losing their power, and we need new ones.
The numbers are hard to ignore. Drug resistance was directly responsible for about 1.14 million deaths in 2021, was linked to nearly five million more and is forecast to keep getting worse for decades.
The usual response is to ask for a scientific breakthrough, the next wonder drug. Science matters, especially when facing new threats, including pathogens that could be engineered or sped up with Artificial Intelligence. However, we cannot assume the right drug will be on the shelf. The barrier is not paying for the drug; it’s finding a way to fund its development.
What differentiates antibiotics from other drugs is that it’s best not to use them until absolutely needed. Antibiotics eventually become less effective as the pathogens they attack build resistance. This means we need to: first, delay introducing new antibiotics (so that the resistance clock does not start ticking); and second, slow resistance by limiting the overuse of antibiotics.
Science isn’t holding us back. We know how to find and develop antibiotics even if the process is challenging. The real trouble is that the standard drug-company business model does not support this kind of medicine. Good medicine and a viable business pull in opposite directions.
We have already seen where this leads. Achaogen and Melinta both brought new antibiotics to market for serious, drug-resistant infections. Both filed for bankruptcy. The problem is not that there is no market for these medicines. It is that a business model based on sales volume is at odds with how these drugs have to be used.
There is a fix being tested. Delinked payment breaks the link between what a company earns and sells. Instead of paying per dose, the government pays a fixed fee for the antibiotic to be available when it is needed. It works more like a subscription than a sale.
The United Kingdom has piloted a model like this since 2022, paying for access to key antibiotics rather than per dose. The United States has proposed something similar in the PASTEUR Act. The idea is straightforward: pay for an effective antibiotic to exist and be ready, rather than paying the company to sell as much of it as possible. This aligns financial incentives with public health goals, rather than working against them.
But the second problem – overusing the antibiotics we have – is also critical. Even a well-funded pipeline cannot keep pace if we keep driving resistance. In practice, we need to prescribe antibiotics only when necessary. This means cutting unnecessary use of antibiotics in agriculture, still a major driver of resistance. It means stopping infections before anyone needs an antibiotic through vaccines, clean water and basic infection control. And it means keeping antibiotic residues and resistant bacteria out of our wastewater and the wider environment, where resistance spreads unseen. Resistance moves freely between people, animals and the environment, so our response must cover all three.
This is the thinking behind the World Health Organization’s updated Global Action Plan on Antimicrobial Resistance, adopted in 2026. The plan underscores paying for the antibiotics we need in a sustainable way and cutting the conditions that drive resistance across human health, agriculture and the environment.
Importantly, Canada is not starting from zero. The Pan-Canadian Action Plan on Antimicrobial Resistance, launched in 2023, is already pushing work on surveillance, stewardship and more careful antibiotic use on farms. That same year, a Council of Canadian Academies expert panel set out to determine how to get critically needed antibiotics to Canadian patients. The groundwork is real, and financing is finally moving. Ottawa’s AMR Innovation Pilot, expected this fall, will pay companies to bring priority antibiotics not sold here to Canadian hospitals.
That pilot should fully delink payment from sales, as the U.K. does, and be funded to match Canada’s fair share of the global burden, which an expert panel put at $14.5 to $18 million a year per drug, with Ottawa and the provinces splitting the cost. This should complement existing efforts to protect new antibiotics through responsible use, reduce agricultural use and invest in infection prevention, surveillance and keeping antibiotic residues and resistant bacteria out of our water.
Sovereignty should also shape how we design any incentive. Most new antibiotics are developed and made by a small number of companies, almost all of them based outside Canada. A Canadian subscription that pays more for finished drugs helps with access, but leaves us dependent on foreign suppliers, and exposed to shortages and export limits. We lived this during the pandemic.
The more resilient goal is to build a Canadian discovery engine that runs end-to-end: a publicly funded, open capability that goes from spotting a new resistant bug, or the next emerging threat, to a drug candidate, with enough domestic manufacturing to produce priority medicines when supply chains seize up. Kept ready, rather than thrown together in the middle of a crisis, is what turns money into preparedness. Better incentives are necessary, as well as aiming them at a Canadian capability that will make us less dependent.
The good news is that much of this is already within reach. We are not waiting on a miracle. The science keeps improving, the economic fixes are being tried in other countries, and work is underway here.
If World AMR Week is a reminder of anything, it is that our two best tools – paying for antibiotics differently and using fewer of them – work best when we use them together.
